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Bromodomain and extra terminal (BET) proteins com-prise the ubiquitously expressed BRD2, BRD3, BRD4and the testes specific BRDT.1,2 These multipurpose pro-
teins contain tandem N-terminal bromodomains that bind
acetylated lysine residues of histone (and non-histone) pro-
teins and other protein modules, such as the extra terminal
domain, and in some (BRD4, BRDT), a C-terminal domain.
They also mediate a number of effects including transcription-
al activation via recruitment of other partner proteins.3
Inhibitors of these proteins are emerging as exciting new ther-
apies for the treatment of hematologic and solid malignancies,
offering the possibility of specifically targeting epigenetic
readers. We and others have already demonstrated the pre-
clinical efficacy of BET inhibitors in acute myeloid leukemia
(AML),4-6 while several other papers have documented similar
efficacy in myeloma,7 non-Hodgkin lymphoma,8 and acute
lymphoblastic leukemia.9 These observations have led to sev-
eral clinical trials that are currently underway to confirm the
efficacy of these drugs in AML and other malignancies. Even
though the most mature trials have recently reported limited
objective responses of monotherapy in heavily pre-treated
AML, lymphoma and myeloma patients,10-12 early data suggest
that combination therapies with other small molecules or
more conventional cytotoxic agents might be particularly
promising.13-15 
BET proteins have multiple functions. Amongst these, and
considered critical for the maintenance of malignant tran-
scription, they are implicated in the regulation of large or
“super” enhancers that control a number of critical genes,
including oncogenes pivotal for the maintenance of
leukemia, such as BCL-2, IRF8, and c-MYC. Their downreg-
ulation upon treatment with small molecule BET inhibitors
at least partially explains the effects of BET inhibition
observed in hematologic and solid malignancies.4,13,15,16
However, despite several ongoing clinical trials, we know
surprisingly little about the consequences of disrupting BET
protein function in normal tissues. In this issue of the
Journal, Wroblewski et al.,17 therefore, address a highly rele-
vant topic and describe the effects of the prototypic BET
inhibitor JQ1 on normal hematopoiesis. 
Surprisingly, upon JQ1 treatment, Wroblewski et al. identi-
fy an increase in phenotypic HSC proliferation and mobiliza-
tion in mice. In addition, these effects seem sustained, and
functionally, in the setting of competitive transplantation,
JQ1 treated HSC appear to contribute more to
hematopoiesis in primary and, importantly, in secondary
recipients with no evidence of exhaustion, albeit follow up
was only for 12 months following transplantation. This
increased proliferation does not enhance radiosensitivity. On
the contrary, JQ1 treated mice show faster count recovery
following sublethal irradiation compared to untreated con-
trols. Although the authors have not studied potential under-
lying mechanisms, they postulate that the effects might be
mediated by JQ1 dependant suppression of Myb,18 given the
phenotypic similarity between JQ1 treatment and a mouse
model of reduced Myb activity.19
Due to its pharmacokinetic properties, JQ1 does not lead
to sustained target inhibition, and due to its limited efficacy
in pre-clinical models, JQ1 has never been tested in clinical
trials.20 Therefore, whether JQ1 induced expansion of the
normal HSC pool described here is a “class effect” shared by
more potent BET inhibitors needs to be carefully addressed
by further studies. This is further called into question by the
toxicity reports from the clinical trials that have consistently
reported hematologic toxicity, in particular, a dose-depen-
dent, non-cumulative, reversible thrombocytopenia,10,11 and
by opposing reports in the literature regarding the effects of
BET inhibition on normal HSC. In a mouse model of con-
trolled BRD4 inhibition, using an inducible transgenic
shRNA, Brd4 silencing caused a significant reduction in
Lineage- Sca-1+ c-kit+ hematopoietic stem cells 12 weeks
after hematopoietic reconstitution.21 However, as RNAi
would not only lead to almost complete loss of Brd4, but
would also target the non-bromodomain dependent func-
tions of the protein, differences between these models,
where inhibitors would only intermittently target the bro-
modomains, might be expected.
Certainly the possibility that BET inhibitors, in addition to
exerting antitumor effects, could enhance recovery of nor-
mal hematopoiesis, especially after combination chemother-
apy, is intriguing and could open up new avenues for the use
of BET inhibitors in clinical practice (Figure 1). Other areas of
utility for BET inhibition, as suggested by Wroblewski et
al.,17 could include mobilization of peripheral blood (PB)
HSC from donors who fail more standard approaches.
However, validation of this study with orally available BET
inhibitors and specific testing of these hypotheses will be
necessary. 
BET inhibitors might also have a role against acute graft-
versus-host disease (GvHD) and, in fact, were initially
designed as immunosuppressives. Wroblewski et al.17 and
others have shown that BET inhibitors impair T-cell func-
tion. Specifically, Wroblewski et al.17 find that JQ1 treatment
causes increased apoptosis in T cells, and this is associated
with reduced expression of the antiapoptotic BCL-2 as meas-
ured by RT-qPCR. Others have demonstrated that treatment
with I-BET151 results in a reduction in the secretion of IL-6,
TNF-α, and IL-12 by stimulated dendritic cells (DCs).22 Both
T cells and DCs are important mediators of GvHD in recipi-
ents of allogeneic stem cell transplant, suggesting that BET
inhibitors may serve as a prophylactic therapy against acute
GvHD. Again, the results suggested by the pre-clinical mod-
els need to be validated in clinical trials and the benefits must
be weighed against the risks of hematologic toxicity, partic-
ularly thrombocytopenia and neutropenia.
In conclusion, BRD4/BET inhibition is becoming a novel
and exciting treatment option in many hematologic and
solid malignancies, and may have novel promising effects
in bone marrow transplantation. However, little is known
about the effects of such treatment in normal tissues and
an ongoing concern has been about the size of the thera-
peutic window. However, some reassurances are provided
by the studies performed by Wroblewski et al. that have
addressed this issue and suggest potentially beneficial
effects on normal hematopoiesis; further studies are war-
ranted to validate and extend these findings. However, a
note of potential caution comes from models of BET
inhibitor resistance that suggest that under the continuous
and sustained selective pressures of BET inhibition, a small
proportion of leukemic stem cells (LSC) survive and that
over time these cells become the dominant clone.
Mechanistically, this appears to occur through the activa-
tion of the ancillary WNT/β-Catenin pathway that allows
escape from BET inhibition. Importantly, resistance to BET
inhibition in this model is only partially reversible on sus-
pending I-BET.23 The evidence from the Fong et al. study,23
coupled with the evidence emerging from clinical trials and
early study of combination therapy, strengthens the argu-
ment for developing rational combination strategies of BET
inhibitors and other agents for patients with hematologic
and solid malignancies. The Wroblewski et al. study17
promises an unexpected but welcome positive effect on
normal hematopoiesis.
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Figure 1. Effects of BET inhibition on normal and dis-
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altered lymphocyte differentiation. Advantageous
effects may occur on mobilization of peripheral blood
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normal HSC and by altering the balance between nor-
mal and leukemic stem cells (LSCs). However, caution
is required due to the demonstrated emergence of
resistance within the leukemia stem cell compart-
ment under sustained BET inhibition in recent pre-
clinical models.
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NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.
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Research on primary patient cells is a compelling chal-lenge for scientists. Although initially limited toshort experiments over hours or days, engrafting
these primary human cells in immunodeficient mice today
allows even more informative investigation to be carried
out over weeks and months. This experiment is fascinat-
ing, probably first because it gives rise to personal and
moral questions about the patient’s avatar. Also, in basic
research, the xenograft is the model to be used to reveal the
stemness properties of a certain population of cancer cells.1
Although today there are some ex vivo alternatives, the
xenograft remains the gold standard technique to study
cancer stem cells which are responsible for cancer initiation
propagation, maintenance and evolution. Uncovering the
presence of primary human leukemic cells in a sample of
mouse tissue 10-16 weeks after injection, demonstrating
the initial engraftment of leukemia initiating cells (LICs)
causes an exhilarating sensation known to only a few
lucky scientists. Absence of graft triggers the opposite sen-
sation of complete disappointment, which has led several
teams to focus their attention on this particular problem
with the xenograft approach. In this issue of Haematologica,
Krevvata et al. put forward fundamental new insights to
help improve xenograft of acute myeloid leukemia (AML)
and myelodysplastic syndrome (MDS).2
Myelodysplastic syndrome and acute myeloid
leukemia are myeloid neoplasms that disrupt normal
hematopoiesis. This group of myeloid leukemias could be
considered as a continuum consisting of a multitude of
different leukemias, including all possible myeloid abnor-
malities. This results in a wide range of severity and
patient overall survival (OS). MDS patients have globally
better OS than AML patients, and some MDS evolve
inevitably towards AML. Interestingly, the first attempts
at AML/MDS xenograft quickly revealed, through the
repartition of samples engrafting and non-engrafting the
mice, that the engraftment potential was perfectly linked
with the aggressiveness of the leukemia, since AML sam-
ples are usually more easy to engraft than MDSs.3,4 Many
independent studies have offered different reasons for
engraftment failure, but none can satisfactorily explain it.
Possible explanations are either related to the host
immune environment or to the defect of the grafted cells
or to the graft and host compatibility.
The innate and adaptive immune response of the host
environment is an obvious and very clear obstacle for the
